Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

B. Chapman, Paul; Hauschild, Axel; Robert, Caroline; B. Haanen, John; Ascierto, Paolo; Larkin, James; Dummer, Reinhard; Garbe, Claus; Testori, Alessandro; Maio, Michele; Hogg, David; Lorigan, Paul; Lebbe, Celeste; Jouary, Thomas; Schadendorf, Dirk; Ribas, Antoni; J. O'Day, Steven; A. Sosman, Jeffrey; M. Kirkwood, John; M.M. Eggermont, Alexander; Dreno, Brigitte; Nolop, Keith; Li, Jiang; Nelson, Betty; Hou, Jeannie; J. Lee, Richard; T. Flaherty, Keith; A. McArthur, Grant

doi:10.1056/nejmoa1103782

Public

Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

Shared by NobleBlocks on Jun 5, 2011 • 12:00 AM UTC

Authors:

P. Chapman

A. Hauschild

C. Robert

Abstract

Background Phase 1 and 2 clinical trials of the BRAF kinase inhibitor vemurafenib (PLX4032) have shown response rates of more than 50% in patients with metastatic melanoma with the BRAF V600E mutation. Methods We conducted a phase 3 randomized clinical trial comparing vemurafenib with dacarbazine in...

Subject

Medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!